Salud financiera de hoja de balance de PHAXIAM Therapeutics

Salud financiera controles de criterios 6/6

PHAXIAM Therapeutics tiene un patrimonio de los accionistas total de €36.6M y una deuda total de €15.1M, lo que sitúa su ratio deuda-patrimonio en 41.3%. Sus activos y pasivos totales son €65.5M y €28.9M respectivamente.

Información clave

41.3%

Ratio deuda-patrimonio

€15.14m

Deuda

Ratio de cobertura de intereses	n/a
Efectivo	€25.19m
Patrimonio	€36.63m
Total pasivo	€28.90m
Activos totales	€65.53m

Actualizaciones recientes sobre salud financiera

Recent updates

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo (€30.9M) de PHXM superan a sus pasivos a corto plazo (€17.4M).

Pasivo a largo plazo: Los activos a corto plazo de PHXM (€30.9M) superan a sus pasivos a largo plazo (€11.5M).

Historial y análisis de deuda-patrimonio

Nivel de deuda: PHXM tiene más efectivo que su deuda total.

Reducción de la deuda: PHXM tenía patrimonio neto negativo hace 5 años, pero ahora es positivo y, por lo tanto, ha mejorado.

Hoja de balance

Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: PHXM tiene suficiente cash runway para más de un año basándose en su flujo de caja libre actual.

Pronóstico de cash runway: PHXM dispone de suficiente cash runway para 1.2 años si el flujo de caja libre sigue creciendo a tasas históricas de 4.1% cada año.

Salud financiera de hoja de balance de PHAXIAM Therapeutics

Salud financiera controles de criterios 6/6

Información clave

Actualizaciones recientes sobre salud financiera

PHAXIAM Therapeutics Announces Intention to Voluntary Delist ADS from Nasdaq Capital Market

PHAXIAM Therapeutics Receives Compliance Notice from Nasdaq

ERYTECH Announces Receipt of Nasdaq Notice

Recent updates

PHAXIAM Therapeutics Announces Enrolment of First Patient in the Phase 1 Study for the Treatment of Endocarditis Infections Caused by Staphylococcus Aureus

PHAXIAM Therapeutics Announces Intention to Voluntary Delist ADS from Nasdaq Capital Market

PHAXIAM Therapeutics S.A. to Report Q2, 2024 Results on Sep 25, 2024

PHAXIAM Therapeutics Obtains Authorizations to Launch Its Phase 1 Study in Endocarditis Infections Caused by Staphylococcus Aureus

PHAXIAM Therapeutics Announces High Coverage Performance of Its Two Anti-Staphylococcus Aureus Phages over Clinical Strains

PHAXIAM Therapeutics Receives Compliance Notice from Nasdaq

PHAXIAM Therapeutics S.A. Announces Launch of New Preclinical Development

PHAXIAM Therapeutics S.A. to Report Q2, 2023 Results on Sep 21, 2023

ERYTECH Pharma S.A.(NasdaqCM:PHXM) dropped from NASDAQ Composite Index

ERYTECH Pharma S.A Announces Management Changes

Erytech Pharma S.A. Approves the Appointment of Robert Sebbag and Eric Leire as Directors

Akkadian Initiates Proceedings to Postpone the Vote on the Merger with Pherecydes

Mediobanca Banca di Credito Finanziario S.p.A. agreed to acquire an unknown minority stake in Anima Holding S.p.A. from Omnes Capital S.A.S., Auriga Partners, Ace Capital Partners, Go Capital SAS and Participations Besançon.

ERYTECH Announces Receipt of Nasdaq Notice

ERYTECH receives non-compliance letter from Nasdaq

ERYTECH Pharma S.A. to Report Q3, 2022 Results on Nov 21, 2022

Erytech Pharma reports 1H results

ERYTECH Pharma to Stop Further Plans to Pursue A BLA Submission Seeking an Approval for Graspa® in Hypersensitive ALL

Erytech drops plans to pursue FDA approval for leukemia therapy

Catalent, Inc. (NYSE:CTLT) acquired Cell therapy manufacturing facility in Princeton, New Jersey of ERYTECH Pharma S.A. (ENXTPA:ERYP) for $44.5 million.

Catalent, Inc. (NYSE:CTLT) entered into an asset purchase agreement to acquire Cell therapy manufacturing facility in Princeton, New Jersey of ERYTECH Pharma S.A. (ENXTPA:ERYP) for $44.5 million.

Catalent, Inc. (NYSE:CTLT) entered into an asset purchase agreement to acquire Cell therapy manufacturing facility in Princeton, New Jersey of ERYTECH Pharma S.A. (ENXTPA:ERYP) for $44.5 million.

ERYTECH Pharma Announces Publication of Positive Results from Eryaspase Phase 2 Trial

ERYTECH Pharma Expands Patent Portfolio for the Treatment of Rare Metabolic Diseases

ERYTECH Pharma Announces Presentation of Results of Two Clinical Trials of Eryaspase in Pancreatic Cancer at ASCO GI

Our First Look At ERYTECH Pharma

ERYTECH Pharma S.A. 2021 Q1 - Results - Earnings Call Presentation

ERYTECH Pharma Announces TRYbeCA-1 Phase 3 Trial in 2L Pancreatic Cancer to Continue to Final Analysis

ERYTECH Pharma Announces First Patient Enrolled in a Phase 1 Investigator Sponsored Trial of Eryaspase in First-Line Pancreatic Cancer

ERYTECH starts patient enrollment in pancreatic cancer study

ERYTECH Completes Enrollment in TRYbeCA-1 Phase 3 Trial in Second-Line Pancreatic Cancer

ERYTECH Pharma S.A. Announces That an Abstract Detailing Results from the NOPHO Sponsored Phase 2 Trial of Eryaspase in All Patients, Has Been Selected for Oral Presentation At the Upcoming 62nd American Society of Hematology (ASH) Annual Meeting

ERYTECH secures €10M in non-dilutive financing

ERYTECH Pharma S.A. to Report Q2, 2021 Results on Sep 20, 2021

ERYTECH Pharma Appoints Stewart Craig as Chief Technical Officer and Member of the Executive Team

ERYTECH: Trials In Pancreatic Cancer

Análisis de la situación financiera

Historial y análisis de deuda-patrimonio

Hoja de balance

Análisis de cash runway

Descubre empresas con salud financiera